220
Participants
Start Date
November 15, 2016
Primary Completion Date
March 3, 2020
Study Completion Date
March 3, 2020
SHR-1210
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Cancer Hospital Chinese Academy of Medical Science, Beijing
Jilin Cancer Hospital, Changchun
Haerbin Medical University Cancer Hospital, Haerbin
Zhangshan Hospital Fudan University, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
81 Hospital Nanjing, Nanjing
The Second Hospital of Anhui Medical University, Hefei
The First Affiliated Hospital of Bengbu Medical College, Bengbu
The First Affiliated Hospital Zhejiang University, Hangzhou
The First Affiliated Hospital of Nanchang University, Nanchang
Fujian Medical University Union Hospital, Fuzhou
Xiangya Hospital Central South University, Changsha
Hunan Cancer Hospital, Changsha
Guangdong General Hospital, Guangzhou
Cancer Hospital of Shantou University Medical College, Shantou
West China Hospital, Chengdu
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY